CDER Conversation: CDER Creates New Biologics Resources for Educators, Teaching Facilities - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. CDER Conversation: CDER Creates New Biologics Resources for Educators, Teaching Facilities FDA's Center for Drug Evaluation and Research's Office of Therapeutic Biologics and Biosimilars (OTBB) released its first-ever curriculum toolkit for educators to help students in healthcare professional degree programs improve their understanding of biosimilar and interchangeable products and their regulatory approval pathway in the U.S. Sarah Yim, M.D., OTBB Director, explains the new educational toolkit and its importance to medicine, nursing, and pharmacy students as well as educators. The toolkit is designed for educators to help students in healthcare professional degree programs for medicine, nursing, physician assistants, and pharmacy improve their understanding about biologics and biosimilars. As these students transition into professional practice, they can play a key role in educating patients about biosimilar and interchangeable products and can work together with patients to decide if one of these products is the best treatment option in a particular clinical case. Learn More This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA